Matches in Wikidata for { <http://www.wikidata.org/entity/Q62811088> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q62811088 description "clinical trial" @default.
- Q62811088 description "ensayu clínicu" @default.
- Q62811088 description "klinisch onderzoek" @default.
- Q62811088 description "клінічне випробування" @default.
- Q62811088 name "Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema" @default.
- Q62811088 type Item @default.
- Q62811088 label "Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema" @default.
- Q62811088 prefLabel "Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema" @default.
- Q62811088 P1132 Q62811088-4331D13B-D838-4CBC-9985-22218C28664D @default.
- Q62811088 P131 Q62811088-C210BE48-90E4-4389-9797-BAF0C734CAB6 @default.
- Q62811088 P1476 Q62811088-8F369C82-FB52-4AC1-9CA7-3BC075096B7C @default.
- Q62811088 P17 Q62811088-0371A6B1-2E61-496D-8311-C447CCA28EC4 @default.
- Q62811088 P17 Q62811088-15D25314-FA09-4EEB-BD2B-3F2246B9E9BC @default.
- Q62811088 P17 Q62811088-3F38DF88-8BDC-4D6A-9FD0-EFE02D458749 @default.
- Q62811088 P17 Q62811088-4905D4D5-5422-4D88-BB8F-3B98B87C8DB6 @default.
- Q62811088 P17 Q62811088-557FEC73-2AA0-40DD-B086-01581F99D753 @default.
- Q62811088 P17 Q62811088-8235097F-0262-4F2D-BB50-44BD9103B19C @default.
- Q62811088 P17 Q62811088-A4771B53-013D-4AAD-A490-0EBCEB66E17C @default.
- Q62811088 P17 Q62811088-B41E827A-ECF6-4982-9EF0-975006540BC9 @default.
- Q62811088 P17 Q62811088-CB9D8A9C-1AD0-49A0-8168-812C284E6B14 @default.
- Q62811088 P17 Q62811088-DC45A005-D311-41A4-A8A7-6E9E7F7D886F @default.
- Q62811088 P17 Q62811088-F8ABBE64-BF94-44B1-B3AB-320A14F0EB97 @default.
- Q62811088 P1813 Q62811088-9294BBC9-F6E4-40DE-AB77-C34E20C21AC4 @default.
- Q62811088 P2899 Q62811088-E73FC697-1D3D-4768-B5B1-90759F4D6598 @default.
- Q62811088 P3098 Q62811088-A9202E62-85D2-41C9-B6C6-FE61FA4F5B95 @default.
- Q62811088 P31 Q62811088-25B350B8-DB91-4973-84B6-F255BBF06D2C @default.
- Q62811088 P580 Q62811088-7B0FEB80-D5F8-47E3-8ABF-2C59E6683DC8 @default.
- Q62811088 P582 Q62811088-4B5FB0B7-878A-4E24-AB83-004967E9034E @default.
- Q62811088 P6099 Q62811088-14CC9BF3-DEFB-4D78-A838-517FC9412F4F @default.
- Q62811088 P6153 Q62811088-D4DB69EA-1474-4F0E-947C-CDBD7974F166 @default.
- Q62811088 P8363 Q62811088-3E0A0C50-EA14-4AE9-97C5-2F23BACE60C5 @default.
- Q62811088 P859 Q62811088-D26BD2CC-BD4B-4D63-9626-A9054D259B86 @default.
- Q62811088 P921 Q62811088-4BC8AB0E-C3F4-424D-9383-75FBEC6C79A3 @default.
- Q62811088 P1132 "+534" @default.
- Q62811088 P131 Q1183 @default.
- Q62811088 P1476 "A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema" @default.
- Q62811088 P17 Q145 @default.
- Q62811088 P17 Q16 @default.
- Q62811088 P17 Q29 @default.
- Q62811088 P17 Q30 @default.
- Q62811088 P17 Q38 @default.
- Q62811088 P17 Q40 @default.
- Q62811088 P17 Q408 @default.
- Q62811088 P17 Q414 @default.
- Q62811088 P17 Q45 @default.
- Q62811088 P17 Q55 @default.
- Q62811088 P17 Q801 @default.
- Q62811088 P1813 "KESTREL" @default.
- Q62811088 P2899 "+18" @default.
- Q62811088 P3098 "NCT03481634" @default.
- Q62811088 P31 Q30612 @default.
- Q62811088 P580 "2018-01-21T00:00:00Z" @default.
- Q62811088 P582 "2020-09-11T00:00:00Z" @default.
- Q62811088 P6099 Q42824827 @default.
- Q62811088 P6153 Q507154 @default.
- Q62811088 P8363 Q78089383 @default.
- Q62811088 P859 Q507154 @default.
- Q62811088 P921 Q25326694 @default.